Cagrilintide + Semaglutide Combination
Evidence Grade C — Moderate human evidence. 34 published studies, 23 human. 0 registered clinical trials.
CagriSema is a single once-weekly injection combining cagrilintide (an amylin analogue) with semaglutide (a GLP-1 agonist), in Phase III development by Novo Nordisk. By targeting two different appetite-control pathways simultaneously, it aims to achieve greater weight loss than semaglutide alone. In the pivotal trial, it achieved 22.7% weight loss — comparable to tirzepatide's results.
34 published studies: 23 human, 1 animal, 0 in-vitro, 20 reviews
CagriSema is in Phase III development (not yet approved). The pivotal REDEFINE-1 trial (3,417 patients, 68 weeks) reported 22.7% weight loss with CagriSema compared to 16.1% with semaglutide alone and 2.3% with placebo. The approximately 6 percentage point advantage over semaglutide alone demonstrates the additive benefit of the amylin component.
CagriSema represents the combination approach to obesity pharmacotherapy — targeting multiple pathways to achieve greater weight loss than monotherapy. Gastrointestinal side effects remain the most common adverse events. If approved, it would be the first injectable combination therapy for obesity.
CagriSema combines two complementary mechanisms: semaglutide's GLP-1 receptor-mediated appetite suppression with cagrilintide's amylin receptor-mediated satiety enhancement. The rationale is that simultaneously targeting two distinct brain pathways controlling food intake produces greater weight loss than either mechanism alone — similar to how combining different blood pressure medications produces greater effect than increasing the dose of one.
The REDEFINE-1 trial (3,417 patients) showed 22.7% weight loss with CagriSema compared to 16.1% with semaglutide alone — a roughly 6 percentage point advantage demonstrating the additive benefit of the amylin component. A regulatory filing was submitted in December 2025, with FDA review expected by approximately late 2026. Initial market expectations of approximately 25% weight loss were modestly overestimated. The actual 22.7% result is comparable to tirzepatide's 22.5% from its pivotal trial, though a head-to-head trial (REDEFINE-4) is ongoing and will provide the first direct comparison. Gastrointestinal side effects occurred in about 80% of patients (primarily nausea and diarrhoea), which is higher than semaglutide alone. If approved, CagriSema would be the first injectable combination therapy for obesity.
Health Canada Market Authorisation
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Liraglutide is marketed as Victoza for type 2 diabetes (approved 2010) and Saxenda for weight management (approved 2014). The LEADER trial, involving over 9,300 patients followed for nearly four years, established that liraglutide reduced the risk of major cardiovascular events by 13% — a landmark finding that helped establish GLP-1 treatments as a class with heart benefits. Saxenda is also approved for adolescents aged 12 and older. While historically significant, liraglutide has been substantially surpassed by newer agents. In a direct comparison, semaglutide achieved 15.8% weight loss compared to liraglutide's 6.4%. Liraglutide remains relevant as a lower-intensity option and as a benchmark against which newer treatments are measured. It has over a decade of real-world safety data, making it one of the best-understood medications in this class.
Setmelanotide is marketed as Imcivree (Rhythm Pharmaceuticals; approved November 2020 for POMC, PCSK1, or LEPR deficiency; June 2022 for Bardet-Biedl syndrome; December 2024 expanded to patients aged 2 years and older). Genetic testing confirming an eligible mutation is required before treatment. In patients with POMC or PCSK1 deficiency, approximately 80% achieved at least 10% weight loss in clinical trials. In Bardet-Biedl syndrome, 32.3% achieved the same threshold. The most common side effects are injection-site reactions and skin darkening (due to the melanocortin pathway's connection to pigmentation). Setmelanotide exemplifies precision medicine — it is highly effective in the specific genetic populations it targets but is not indicated for common obesity.
HGH Fragment 176-191 has no marketing authorisation. A Phase IIa trial in obesity (approximately 300 patients) failed to demonstrate statistically significant weight loss at any dose tested. The clinical development programme was discontinued. The disconnect between animal data (which showed significant fat reduction in obese mice) and the failed human trial is the defining feature of this compound's development history. Products available through unregulated channels lack pharmaceutical quality assurance. The failed Phase II trial represents the highest level of clinical evidence available.
